Literature DB >> 1347190

The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine.

E B Gurvich1.   

Abstract

The use of vaccinia virus in recombinant systems may result in the occurrence of complications observed following smallpox vaccination. The results are presented of a large survey carried out in the USSR between 1968 and 1979. High complication rates are reported, particularly in older primary vaccinees; for example, there were 312.5 cases of neurological complications per million in those aged greater than or equal to 5 years. The author concludes that this factor will limit the use of vaccinia virus in recombinant technology.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1347190     DOI： 10.1016/0264-410x(92)90023-d

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion.

Authors:  R E Toes; R C Hoeben; E I van der Voort; M E Ressing; A J van der Eb; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

3.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

Authors:  L H Nguyen; D M Knipe; R W Finberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Frequency of adverse events after vaccination with different vaccinia strains.

Authors:  Mirjam Kretzschmar; Jacco Wallinga; Peter Teunis; Shuqin Xing; Rafael Mikolajczyk
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

5.  Comparing New-Generation Candidate Vaccines against Human Orthopoxvirus Infections.

Authors:  R A Maksyutov; S N Yakubitskyi; I V Kolosova; S N Shchelkunov
Journal:  Acta Naturae       Date:  2017 Apr-Jun       Impact factor: 1.845

Review 6.  Swinepox virus as a vaccine vector for swine pathogens.

Authors:  D N Tripathy
Journal:  Adv Vet Med       Date:  1999

7.  Enhancing the Immunogenicity of Vaccinia Virus.

Authors:  Sergei N Shchelkunov; Stanislav N Yakubitskiy; Alexander A Sergeev; Ekaterina V Starostina; Ksenia A Titova; Stepan A Pyankov; Galina A Shchelkunova; Mariya B Borgoyakova; Alexey M Zadorozhny; Lyubov A Orlova; Denis N Kisakov; Larisa I Karpenko
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.